Search form

Home
LoginSubscribe
  • Home
  • Country Intelligence
  • Industry Directory
  • Offsets / IC
  • Tenders
    • Haiti(0/week)
    • Guyana(0/week)
    • Honduras(0/week)
    • Jamaica(0/week)
    • Netherlands Antilles(0/week)
    • View all (0/week)
  • News
    • United States(1582/week)
    • Manufacturing(760/week)
    • Energy(604/week)
    • Technology(1443/week)
    • Oil/Gas(129/week)
  • Events
  • About us
    • Who we are
    • Our People
    • Partners
    • Contact us
  • LinkedIn
  • Login
  • Twitter
  • Register
  • Home
  • News

Trastuzumab emtansine

Nov 28, 2019
Health Canada approves Kadcyla® (trastuzumab emtansine) for the treatment of HER2-positive early breast cancer after surgery(1)
Sep 09, 2019
Daiichi Sankyo Advances [Fam-] Trastuzumab Deruxtecan (DS-8201) in Japan with Regulatory Submission in HER2 Positive Metastatic Breast Cancer
Jun 04, 2019
RemeGen, Ltd. Announces Positive Results from RC48 Clinical Trial in HER2-Positive Metastatic or Unresectable Urothelial Cancer
Apr 29, 2019
Daiichi Sankyo Announces Two Lancet Oncology Publications of Phase 1 Dose Expansion Results of [Fam-] Trastuzumab Deruxtecan in HER2 Positive Metastatic Breast and Gastric Cancer
Mar 28, 2019
Daiichi Sankyo and AstraZeneca Announce Global Development and Commercialization Collaboration for Daiichi Sankyo's HER2 Targeting Antibody Drug Conjugate [Fam-] Trastuzumab Deruxtecan (DS-8201)
Mar 28, 2019
Daiichi Sankyo Confirms Plans to Accelerate BLA Submission to U.S. FDA for [Fam-] Trastuzumab Deruxtecan (DS-8201) in HER2 Positive Metastatic Breast Cancer Post T-DM1
Jan 23, 2019
Antibody Drug Conjugate Market Size Worth USD 9.93 Billion By 2025: Grand View Research, Inc.
Jan 14, 2019
Daiichi Sankyo Initiates Pivotal Phase 3 Trial of [Fam-] Trastuzumab Deruxtecan (DS-8201) in HER2 Low Metastatic Breast Cancer
Dec 08, 2018
Daiichi Sankyo Presents Updated Phase 1 Results of [Fam-] Trastuzumab Deruxtecan (DS-8201) in Patients with HER2 Low Expressing Metastatic Breast Cancer at 2018 San Antonio Breast Cancer Symposium (SABCS)
Nov 27, 2018
Daiichi Sankyo and Roche to Collaborate on New HER2 Low Companion Diagnostic Test
Oct 21, 2018
Daiichi Sankyo Presents Updated Results of [Fam-] Trastuzumab Deruxtecan (DS-8201) in Patients with HER2 Expressing Advanced Colorectal Cancer at 2018 European Society for Medical Oncology (ESMO) Congress
May 31, 2018
Daiichi Sankyo Initiates Phase 2 Study of DS-8201 in Patients with Advanced HER2-Overexpressing or HER2-Mutated Non-Squamous Non-Small Cell Lung Cancer
May 16, 2018
Daiichi Sankyo to Present New Data on Multiple Compounds Including Antibody Drug Conjugates DS-8201 and U3-1402 at 2018 American Society of Clinical Oncology (ASCO) Annual Meeting
Mar 27, 2018
Daiichi Sankyo's HER2-Targeting Antibody Drug Conjugate DS-8201 Receives SAKIGAKE Designation for Gastric Cancer from Japan MHLW
Mar 23, 2018
Caris Life Sciences Announces Published Results Showing that its ADAPT Biotargeting System Effectively Stratified Breast Cancer Patients Based on Their Benefit from Trastuzumab Treatment (Herceptin)
Jan 18, 2018
Daiichi Sankyo Presents Updated Data for DS-8201 in Patients with HER2-Expressing Gastric Cancer at ASCO 2018 Gastrointestinal Cancers Symposium
Dec 07, 2017
Daiichi Sankyo Presents Updated Data for DS-8201 in Patients with HER2-Expressing Breast Cancer at San Antonio Breast Cancer Symposium
Oct 24, 2017
Goodwin Biotechnology and For-Robin Collaborated to Generate a Unique Antibody : Drug Conjugate (ADC) that Shows Promise in Enhancing the Treatment of a Variety of Cancers
Sep 28, 2017
Antibody Drug Conjugates Market Grow at 21.82% CAGR By 2022, Analysis by Adcetris, Kadcyla and Pipeline Drugs
Sep 11, 2017
Daiichi Sankyo Presents New Data for DS-8201 in Multiple HER2-Expressing Solid Tumors at European Society for Medical Oncology (ESMO) 2017 Congress
  •  
  • Page 1
  • ››

Latest News

May 10, 2025

Pembina Pipeline Corporation Reports Voting Results from 2025 Annual Meeting of Shareholders

May 10, 2025

Cameco Announces Election of Directors

May 10, 2025

Aqua Pennsylvania Awarded $17.3 Million in Funding to Remove PFAS from Drinking Water, Replace Lead Service...

May 10, 2025

Obsidian Solutions Group Joins Groundbreaking Initiative to Support NASA and the Firefighting Community With...

May 10, 2025

'Pragmatic' approach could reap 'ambitious' UK-EU deal: Starmer

May 10, 2025

HERO ESPORTS ASIAN CHAMPIONS LEAGUE REVEALS VALORANT CHAMPIONS TOUR SCHEDULE AND ESPORTS WORLD CUP...

May 10, 2025

Magellan Aerospace Corporation Announces Financial Results

May 10, 2025

NGL Energy Partners Announces Earnings Call

View all News

Agenda

23
September
United KingdomLondon, UK
Countering Explosive Threat & Demining conference, September 23 - 24, 2025, London, UK
Countering Explosive Threat & Demining conference | September 23 - 24, 2025 | London, UK The Countering Explosive...
21
May
United KingdomLondon, UK
Space Operations Summit, 21 - 22 May 2025, London, UK
Space Operations Summit | 21 - 22 May, 2025 | London, UK Space Operations Summit 2025 is the only conference to look at...
13
May
United States of AmericaWestin Lake Las Vegas Resort and Spa, Henderson, NV
Air Dominance Summit, May 13 - 14, 2025, Westin Lake Las Vegas Resort and Spa, Henderson, NV
Air Dominance Summit | May 13 - 14, 2025 | Westin Lake Las Vegas Resort and Spa, Henderson, NV SECURING AIR SUPREMACY...
View All Events

SUBSCRIBE

to Epicos.com
Please register in order to have access to personalized daily information on world-wide A&D industry developments and business opportunities.
Subscribe

REGISTER

for Epicos.com Newsletter
Sign up for our free newsletters and receive twice a week news and intelligence regarding the Aerospace & Defence Industry, meticulously selected by our editorial team.
Sign Up
Home
  • SIGN UP FOR NEWSLETTER
  • NEWSLETTER ARCHIVE
  • ADVERTISE WITH US
  • CONTACT US
  • PRIVACY POLICY
  • INFORMATION SECURITY POLICY
© 2025 EPICOS
Made by Wedia